Artificial Intelligence-assisted cardiovascular risk stratification for supporting therapeutic decision-making
Tropical Journal of Pharmaceutical Research · 30.04.2026 · 25 (4) · 581-591
DOI: 10.4314/tjpr.v25i4.15 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Journal of Pharmaceutical Research, online erschienen am 30.04.2026. Verfasst von Babitha L und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To apply Hybrid Feature Deep Learning (HFEDL) and structured feature-selection framework (Selected Features) model to develop algorithm for enhanced preventive cardiovascular disease risk prediction.
Methods
The HFEDL model is a hybrid feature-engineering and deep-learning method that improves learning dynamics, whereas the structured feature-selection framework is based on statistically significant features to achieve higher classification accuracy. Benchmark datasets have been used to compare various models, including traditional deep learning and the random forest classifier.
Results
The HFEDL model achieved 97.5 % testing accuracy and 0.2 loss, the quickest convergence period (15 epochs), and generalization. The structured feature-selection framework model was also able to achieve 90.8 %, and the model had a steady performance. The models generated significant outcomes that were better in terms of accuracy, training efficiency, and generalization (5/5) when compared to traditional state-of-the-art models; thus, the models may be considered to offer real-time clinical decision support. The predicted risk levels support therapeutic decision-making by guiding pharmacological interventions such as statins, antihypertensive therapy, and patient monitoring strategies.
Conclusion
The HFEDL model has better predictive capability than traditional machine learning and isolated deep learning models, and the feature-selection framework is more interpretable and less complex to calculate because it identifies clinically meaningful variables. Combining feature selection with hybrid deep learning constitutes a trade-off between accuracy, efficiency, and interpretability.
Zitieren
APA
L, B., & K, S. (2026). Artificial Intelligence-assisted cardiovascular risk stratification for supporting therapeutic decision-making. Tropical Journal of Pharmaceutical Research, 25(4), 581-591. https://doi.org/10.4314/tjpr.v25i4.15
Vancouver
L B, K S. Artificial Intelligence-assisted cardiovascular risk stratification for supporting therapeutic decision-making. Tropical Journal of Pharmaceutical Research. 2026;25(4):581-591. doi:10.4314/tjpr.v25i4.15
BibTeX
@article{L2026,
author = {L, Babitha and K, Sundara},
title = {Artificial Intelligence-assisted cardiovascular risk stratification for supporting therapeutic decision-making},
journal = {Tropical Journal of Pharmaceutical Research},
year = {2026},
volume = {25},
number = {4},
pages = {581--591},
doi = {10.4314/tjpr.v25i4.15}
}
EUVIMED